Lyell Immunopharma (LYEL) Income Statement (2020 - 2026)
Income Statement report data from Jun 30, 2020 to Mar 31, 2026 for Lyell Immunopharma (LYEL).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||||||
Total Revenue | - | 10K (-50.00%) | 20K (+100.00%) | 10K (0.00%) | 10K (0.00%) | 10K (-66.67%) | 30K (+200.00%) | 10K | - | 10K (-66.67%) | 30K (0.00%) | 30K (-57.14%) | 70K (-99.86%) | 48M | - | 36M (+6398.18%) | 550K (-80.50%) | 2.82M (+2.17%) | 2.76M (+4.94%) | 2.63M (+7.79%) | 2.44M (+128.04%) | 1.07M (-65.71%) | 3.12M |
Operating Expenses | |||||||||||||||||||||||
Research And Development | 37M (-29.89%) | 52M (+85.30%) | 28M (-19.19%) | 35M (-19.77%) | 43M (-10.73%) | 49M (+23.22%) | 40M (-1.89%) | 40M (-6.74%) | 43M (-8.15%) | 47M (+7.18%) | 44M (-7.63%) | 47M (+6.36%) | 45M (+17.35%) | 38M (-8.60%) | 42M (-4.83%) | 44M (+22.02%) | 36M (+85.74%) | 19M (-38.63%) | 31M (-32.34%) | 46M (+11.85%) | 42M (+69.51%) | 25M (-74.78%) | 97M |
Selling General And Administrative | 9.56M (-9.98%) | 11M (-0.65%) | 11M (+9.19%) | 9.79M (-30.32%) | 14M (-3.24%) | 15M (+23.36%) | 12M (-4.00%) | 12M (-9.12%) | 13M (+2.43%) | 13M (-15.09%) | 16M (-18.50%) | 19M (-1.30%) | 19M (-26.83%) | 26M (+1.04%) | 26M (-14.35%) | 30M (-11.53%) | 34M (+8.00%) | 32M (+50.05%) | 21M (+11.15%) | 19M (+13.55%) | 17M (+24.02%) | 14M (+41.95%) | 9.56M |
Operating Expenses | 44M (-65.33%) | 128M (+242.50%) | 37M (-20.95%) | 47M (-17.81%) | 57M (-71.48%) | 201M (+298.02%) | 51M (-1.94%) | 52M (-7.27%) | 56M (-6.62%) | 60M (+0.78%) | 59M (-10.42%) | 66M (+5.29%) | 63M (-0.87%) | 63M (-4.92%) | 66M (-8.99%) | 73M (+5.60%) | 69M (+37.27%) | 50M (-3.00%) | 52M (-20.53%) | 65M (+12.99%) | 58M (+52.52%) | 38M (-64.13%) | 106M |
Depreciation And Amortization | 2.33M (-71.23%) | 8.10M | - | - | 3.44M (-76.45%) | 15M | - | - | 5.02M (-67.02%) | 15M | - | - | 5.03M (-63.63%) | 14M | - | - | 4.19M (-64.10%) | 12M | - | - | 1.96M | - | - |
Operating Income | |||||||||||||||||||||||
Operating Income | -44.26M (-65.32%) | -127.64M (+242.66%) | -37.25M (-20.98%) | -47.14M (-17.83%) | -57.37M (-71.48%) | -201.15M (+298.32%) | -50.50M (-2.00%) | -51.53M (-7.27%) | -55.57M (-6.62%) | -59.51M (+0.80%) | -59.04M (-10.41%) | -65.90M (+5.34%) | -62.56M (+323.27%) | -14.78M (-77.75%) | -66.44M (+78.31%) | -37.26M (-45.67%) | -68.58M (+44.26%) | -47.54M (-3.30%) | -49.16M (-21.61%) | -62.71M (+13.26%) | -55.37M (+50.30%) | -36.84M (-64.08%) | -102.57M |
Ebit | -44.26M (-65.32%) | -127.64M (+242.66%) | -37.25M (-20.98%) | -47.14M (-17.83%) | -57.37M (-71.48%) | -201.15M (+298.32%) | -50.50M (-2.00%) | -51.53M (-7.27%) | -55.57M (-6.62%) | -59.51M (+0.80%) | -59.04M (-10.41%) | -65.90M (+5.34%) | -62.56M (+323.27%) | -14.78M (-77.75%) | -66.44M (+78.31%) | -37.26M (-45.67%) | -68.58M (+44.26%) | -47.54M (-3.30%) | -49.16M (-21.61%) | -62.71M (+13.26%) | -55.37M (+50.30%) | -36.84M (-64.08%) | -102.57M |
EBITDA | -41.93M (-65.75%) | -122.41M (+215.08%) | -38.85M (-8.97%) | -42.68M (-20.86%) | -53.93M (-72.79%) | -198.18M (+344.55%) | -44.58M (-2.69%) | -45.81M (-9.38%) | -50.55M (-7.23%) | -54.49M (+7.16%) | -50.85M (-20.41%) | -63.89M (+11.06%) | -57.53M | 1.93M | -70.25M (+93.42%) | -36.32M (-43.59%) | -64.39M (+77.53%) | -36.27M (-25.78%) | -48.87M (-21.92%) | -62.59M (+17.19%) | -53.41M (+49.52%) | -35.72M (-64.51%) | -100.66M |
Other Income / Expenses | |||||||||||||||||||||||
Other Non Operating Income | 18M | -18.12M (+272.84%) | -4.86M | 1.18M (-9.92%) | 1.31M (-72.07%) | 4.69M | -40.00K (-93.75%) | -640.00K | 1.09M (-41.08%) | 1.85M (+17.09%) | 1.58M | -330.00K | 1.10M (-41.80%) | 1.89M | -1.07M (+10600.00%) | -10.00K | 40K | -160.00K | 20K | -110.00K (+266.67%) | -30.00K | 30K (0.00%) | 30K |
Net Income | |||||||||||||||||||||||
Net Income From Continuing Operations | -24.15M (-82.84%) | -140.72M (+262.21%) | -38.85M (-8.97%) | -42.68M (-18.22%) | -52.19M (-72.81%) | -191.93M (+330.53%) | -44.58M (-2.69%) | -45.81M (-24.49%) | -60.67M (+14.62%) | -52.93M (+4.09%) | -50.85M (-20.41%) | -63.89M (-4.58%) | -66.96M (+697.14%) | -8.40M (-88.04%) | -70.25M (+93.42%) | -36.32M (-46.70%) | -68.14M (-18.60%) | -83.71M (+71.29%) | -48.87M (-21.92%) | -62.59M (+13.72%) | -55.04M (+54.09%) | -35.72M (-64.51%) | -100.66M |
Net Income | -24.15M (-82.84%) | -140.72M (+262.21%) | -38.85M (-8.97%) | -42.68M (-18.22%) | -52.19M (-72.81%) | -191.93M (+330.53%) | -44.58M (-2.69%) | -45.81M (-24.49%) | -60.67M (+14.62%) | -52.93M (+4.09%) | -50.85M (-20.41%) | -63.89M (-4.58%) | -66.96M (+697.14%) | -8.40M (-88.04%) | -70.25M (+93.42%) | -36.32M (-46.70%) | -68.14M (-18.60%) | -83.71M (+71.29%) | -48.87M (-21.92%) | -62.59M (+13.72%) | -55.04M (+54.09%) | -35.72M (-64.51%) | -100.66M |
Comprehensive Income Net Of Tax | -24.40M (-91.11%) | -274.50M (+609.30%) | -38.70M (-9.54%) | -42.78M (-18.25%) | -52.33M (-84.73%) | -342.61M (+688.88%) | -43.43M (-5.17%) | -45.80M (-24.89%) | -60.98M (-73.15%) | -227.13M (+357.46%) | -49.65M (-20.42%) | -62.39M (-1.34%) | -63.24M (-66.56%) | -189.09M (+162.99%) | -71.90M (+88.86%) | -38.07M (-47.93%) | -73.12M (-71.00%) | -252.10M (+414.38%) | -49.01M (-21.81%) | -62.68M (+13.67%) | -55.14M (+51.82%) | -36.32M (-63.88%) | -100.55M |